Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes

Expert Review of Molecular Diagnostics

Volumn 12, Issue 3, 2012, Pages 253-264

  Jacoby, Meagan A ^a   Walter, Matthew J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

AML; array CGH; copy number alterations; genomics; MDS; SNP array; whole genome sequencing

Indexed keywords

DNA; DNA METHYLTRANSFERASE 3A; NUCLEOPORIN 98; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ASXL1 GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER ALTERATION; COPY NUMBER VARIATION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; GENE TRANSLOCATION; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; MYELODYSPLASTIC SYNDROME; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TET2 GENE;

COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; GENE DOSAGE; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE DELETION;

EID: 84859383178     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.12.18     Document Type: Review

References (68)

1. Haase D, Germing U, Schanz J et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110(13), 4385-4395 (2007).
2. Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5), 937-951 (2009).
3. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6), 2079-2088 (1997).
4. Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J. Clin. Oncol. 25(23), 3503-3510 (2007).
5. Dohner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115(3), 453-474 (2010).
6. Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361(11), 1058-1066 (2009).
7. Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med., 363(25), 2424-2433 (2010).
8. O'Keefe CL, Tiu R, Gondek LP et al. High-resolution genomic arrays facilitate detection of novel cryptic chromosomal lesions in myelodysplastic syndromes. Exp. Hematol. 35(2), 240-251 (2007).
9. Paulsson K, Heidenblad M, Strombeck B et al. High-resolution genome-wide array-based comparative genome hybridization reveals cryptic chromosome changes in AML and MDS cases with trisomy 8 as the sole cytogenetic aberration. Leukemia 20(5), 840-846 (2006).
10. Thiel A, Beier M, Ingenhag D et al. Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance. Leukemia 25(3), 387-399 (2011).
11. + cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival. Blood 112(8), 3412-3424 (2008).
12. Graubert TA, Payton MA, Shao J et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One 4(2), e4583 (2009).
13. Suela J, Alvarez S, Cigudosa JC. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res. 118(2-4), 304-309 (2007).
14. Heinrichs S, Look AT. Identification of structural aberrations in cancer by SNP array analysis. Genome Biol. 8(7), 219 (2007).
15. Heinrichs S, Li C, Look AT. SNP array analysis in hematologic malignancies: avoiding false discoveries. Blood 115(21), 4157-4161 (2010). Highlights the importance of using paired tumor and normal DNA in SNP array analysis of hematologic malignancies using patient examples.
16. O'Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood 115(14), 2731-2739 (2010).
17. Delhommeau F, Jeziorowska D, Marzac C, Casadevall N. Molecular aspects of myeloproliferative neoplasms. Int. J. Hematol. 91(2), 165-173 (2010).
18. Tiu RV, Visconte V, Traina F, Schwandt A, Maciejewski JP. Updates in cytogenetics and molecular markers in MDS. Curr. Hematol. Malig. Rep. 6(2), 126-135 (2011).
19. Mullighan CG, Goorha S, Radtke I et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446(7137), 758-764 (2007).
20. Mullighan CG, Miller CB, Radtke I et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453(7191), 110-114 (2008).
21. Mullighan CG, Phillips LA, Su X et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322(5906), 1377-1380 (2008).
22. Heinrichs S, Kulkarni RV, Bueso-Ramos CE et al. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia 23(9), 1605-1613 (2009). A large study in myelodysplastic syndromes that rigorously used paired tumor and normal DNA in a genome-wide SNP analysis. Experimentally demonstrates the importance of paired samples to definitively identify somatic lesions.
23. Gondek LP, Haddad AS, O'Keefe CL et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp. Hematol. 35(11), 1728-1738 (2007).
24. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111(3), 1534-1542 (2008).
25. Mohamedali A, Gaken J, Twine NA et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110(9), 3365-3373 (2007).
26. Radtke I, Mullighan CG, Ishii M et al. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc. Natl Acad. Sci. USA 106(31), 12944-12949 (2009).
27. Tiu RV, Gondek LP, O'Keefe CL et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 117(17), 4552-4560 (2011).
28. Tyybakinoja A, Elonen E, Piippo K, Porkka K, Knuutila S. Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia 21(3), 571-574 (2007).
29. Suela J, Alvarez S, Cifuentes F et al. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 21(6), 1224-1231 (2007).
30. Barresi V, Romano A, Musso N et al. Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes. Genes Chromosomes Cancer 49(11), 1014-1023 (2010).
31. Gupta M, Raghavan M, Gale RE et al. Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 47(9), 729-739 (2008).
32. Tiu RV, Gondek LP, O'Keefe CL et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J. Clin. Oncol. 27(31), 5219-5226 (2009).
33. Walter MJ, Payton JE, Ries RE et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc. Natl Acad. Sci. USA 106(31), 12950-12955 (2009). A large study in adult acute myeloid leukemia that rigorously used paired tumor and normal DNA in a genome-wide high-resolution SNP analysis and validated results using an orthogonal array platform. This study demonstrates the use of an unbiased high-resolution genomic screen to identify genes that may be relevant for pathogenesis in acute myeloid leukemia.
34. Walter MJ, Shen D, Ding L et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl. J. Med. 366(12), 1090-1098 (2012).
35. Solomon DA, Kim T, Diaz-Martinez LA et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 333(6045), 1039-1043 (2011).
36. Bullinger L, Kronke J, Schon C et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia 24(2), 438-449 (2010).
37. Parkin B, Erba H, Ouillette P et al. Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. Blood 116(23), 4958-4967 (2010).
38. Lorsbach RB, Moore J, Mathew S, Raimondi SC, Mukatira ST, Downing JR. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17(3), 637-641 (2003).
39. Delhommeau F, Dupont S, Della Valle V et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360(22), 2289-2301 (2009). Used array platforms to identify TET2 as an important recurrent mutation in myeloid malignancies.
40. Langemeijer SM, Kuiper RP, Berends M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41(7), 838-842 (2009).
41. Mohamedali AM, Smith AE, Gaken J et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J. Clin. Oncol. 27(24), 4002-4006 (2009).
42. Jankowska AM, Szpurka H, Tiu RV et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 113(25), 6403-6410 (2009).
43. Sanada M, Suzuki T, Shih LY et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460(7257), 904-908 (2009).
44. Dunbar AJ, Gondek LP, O'Keefe CL et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 68(24), 10349-10357 (2008).
45. Makishima H, Cazzolli H, Szpurka H et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J. Clin. Oncol. 27(36), 6109-6116 (2009).
46. Nikoloski G, Langemeijer SM, Kuiper RP et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42(8), 665-667 (2010).
47. Ernst T, Chase AJ, Score J et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 42(8), 722-726 (2010).
48. Makishima H, Jankowska AM, Tiu RV et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 24(10), 1799-1804 (2010).
49. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J. Clin. Oncol. 19(5), 1405-1413 (2001).
50. Bowen D, Groves MJ, Burnett AK et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 23(1), 203-206 (2009).
51. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 22(8), 1539-1541 (2008).
52. Jasek M, Gondek LP, Bejanyan N et al. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia 24(1), 216-219 (2010).
53. Gelsi-Boyer V, Trouplin V, Adelaide J et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 145(6), 788-800 (2009).
54. Boultwood J, Perry J, Pellagatti A et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24(5), 1062-1065 (2010).
55. Ley TJ, Mardis ER, Ding L et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456(7218), 66-72 (2008). First complete sequence of a cancer genome and its matched normal counterpart. This study established the utility of whole-genome sequencing (WGS) to detect acquired mutations in cancer.
56. Graubert TA, Shen D, Ding L et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nature Genetics 44(1), 53-57 (2011).
57. Yoshida K, Sanada M, Shiraishi Y et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478(7367), 64-69 (2011).
58. Ding L, Ley TJ, Larson DE et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382), 506-510 (2012).
59. Link DC, Schuettpelz LG, Shen D et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305(15), 1568-1576 (2011).
60. Welch JS, Westervelt P, Ding L et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 305(15), 1577-1584 (2011). This study demonstrated the utility of WGS to detect a cryptic PML-RARA fusion, which changed the treatment course of the patient. This shows that WGS can identify potentially actionable cryptic fusions in a clinically relevant time frame.
61. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319), 1109-1113 (2010).
62. Maher CA, Kumar-Sinha C, Cao X et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 458(7234), 97-101 (2009).
63. Stephens PJ, Greenman CD, Fu B et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144(1), 27-40 (2011). Uses WGS to characterize the phenomenon of chromothripsis, where massive genomic rearrangements occur during a single event.
64. Roychowdhury S, Iyer MK, Robinson DR et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3(111), 111ra121 (2011).
65. Ebert BL, Pretz J, Bosco J et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451(7176), 335-339 (2008).
66. Yang X, Boehm JS, Salehi-Ashtiani K et al. A public genome-scale lentiviral expression library of human ORFs. Nat. Methods 8(8), 659-661 (2011).
67. Hahn CK, Berchuck JE, Ross KN et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16(4), 281-294 (2009).
68. Graubert T, Walter MJ. Genetics of myelodysplastic syndromes: new insights. Hematol. Am. Soc. Hematol. Educ. Program 2011, 543-549 (2011).